Shanghai Pharmaceutical Group Co., Ltd. is a large-scale pharmaceutical state-controlled listed company (stock code 6167) covering the whole industrial chain of pharmaceutical R&D, manufacturing, distribution and retail, and is a leading enterprise in developing biomedical industry in Shanghai. The shareholders of Shanghai Pharmaceutical Group Co., Ltd. are composed of Shanghai Pharmaceutical (Group) Co., Ltd., SIC, Shanghai SIC, Shanghai Shengrui Investment Co., Ltd., Shenneng (Group) Co., Ltd. and other public shareholders, and Shanghai State-owned Assets Supervision and Administration Commission holds Shanghai Pharmaceutical through the above companies.

Shanghai Pharmaceutical Group Co., Ltd. owns Academia Sinica, 3 national technical centers and 14 provincial (city) technical centers, and has established long-term strategic cooperative relations with more than 8 famous scientific research institutes, including Institute of Pharmacy, Chinese Academy of Sciences. It has successfully developed 277 national new drugs and applied for more than 1 national "major new drug creation" major scientific and technological projects. It has a number of core manufacturing enterprises, such as Xinya Pharmaceutical, Xinyi, Guangdong Tianpu, First Biochemical, Traditional Chinese Medicine, Medicinal Materials, Qingdao Guofeng, Hu Qingyutang and Zhengda Qingchunbao, which produce products covering chemical preparations, biological preparations, traditional Chinese medicine and health care products, chemical raw materials, etc. There are more than 3, drug production approvals, including 198 listed in the National Essential Drugs List, 156 exclusive varieties and 8 confidential varieties of traditional Chinese medicine. It has more than 2 well-known brands including Xinyi, Leishi, Longhu and other well-known trademarks in China, and has sold more than 1 million products in cardiovascular and cerebrovascular diseases, anti-infection, digestive system, nervous system, anti-tumor and other therapeutic fields. The distribution scale ranks the largest in East China and Shanghai, and the second in China. The distribution channels are all over 3 provinces and cities in China, and the proportion of pure sales to sales revenue reaches 65%. We have established important partnerships with 36 of the top 5 multinational pharmaceutical companies in the world and 91 of the top 1 pharmaceutical companies in China, and maintained close business relations with more than 4, international and domestic customers, operating more than 1, varieties. There are 1 logistics bases and nearly 2, retail chain pharmacies in 8 provinces and cities in China.